Estrella Immunopharma, Inc. ESLA
0.48
0.01
2.13%
as of 25 Sep
- Market cap
- $20.5M
- P/E
- 0.0×
Follow ESLA
| Dec '17 | Jan '21 | Jun '21 | Dec '21 | Jan '22 | Dec '22 | Jun '23 | Jun '24 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Current Ratio |
— | 8.42 | 0.00 | 8.42 | 0.05 | 0.05 | 0.28 | 24.65 | 0.55 | 0.12 |
Net Debt/EBITDA |
— | 1.92 | 0.00 | 1.92 | (0.29) | (0.29) | 0.22 | 0.57 | 0.21 | 0.11 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 4.99% | 5.13% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
— | 0.00 | — | 0.00 | 0.07 | (0.22) | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
— | 1.28 | 0.01 | 0.18 | 1.05 | 3.39 | 0.12 | 2.20 | 0.70 | 0.14 |
Capex/Depreciation |
— | — | 0.00 | — | — | — | — | — | — | — |
Interest Coverage |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| — | (1.15%) | 0.00% | (8.30%) | (32.85%) | (12.78%) | 158.80% | 195.79% | (200.44%) | 255.59% | |
| — | (1.08%) | (1.08%) | (7.83%) | (3.57%) | (3.12%) | (174.31%) | (195.43%) | (116.58%) | (413.55%) | |
ROIC |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (4,226.47%) | 0.00% | 0.00% |
Return on Tangible Assets |
— | (45.63%) | (180.54%) | (330.20%) | 97.59% | 30.16% | 158.64% | (171.09%) | 326.43% | 110.09% |
Research and Development Expense of Revenue |
— | — | 0.00% | — | — | — | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
— | 0.00% | 0.00% | — | 0.00% | — | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | — | — | — | — | — | 0.00% | 0.00% | 0.00% | 0.00% |
Free Cash Flow per Share |
— | (0.05) | 0.00 | (0.27) | (0.18) | (0.74) | (4.37) | (0.59) | (0.09) | (0.05) |
Cash per Share |
— | 0.08 | — | 0.41 | 0.01 | 0.03 | 8.11 | 0.15 | 0.03 | 0.04 |
Shareholders Equity per Share |
— | 7.55 | — | (0.85) | 1.23 | (1.59) | (22.06) | 0.16 | 0.00 | (0.28) |
Interest Debt per Share |
— | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | 7.55 | — | (0.85) | 1.23 | (1.59) | (22.06) | 0.16 | 0.00 | (0.28) |
Free Cash Flow |
— | (0.32) | 0.00 | (0.32) | (1.04) | (1.04) | (1.34) | (16.07) | (3.11) | (1.79) |
Working Capital |
— | 0.54 | 0.14 | 0.54 | (1.02) | (1.02) | (7.01) | 4.27 | (1.36) | (11.87) |
Capital Expenditures |
— | — | 0.00 | — | — | — | — | — | — | — |
Net Current Asset Value |
— | (1.01) | 0.14 | (46.19) | (2.86) | (11.93) | (7.02) | 4.27 | (1.36) | (11.87) |
| Other line items | ||||||||||
Quick Ratio |
— | 6.54 | — | 6.54 | 0.04 | 0.04 | 0.25 | 23.05 | 0.31 | 0.10 |
Depreciation/Fixed assets |
— | — | 0.00 | — | — | — | — | — | — | — |
Cash ROIC |
— | (0.71%) | 0.00% | 59.97% | (13.72%) | 60.82% | 31.34% | (190.41%) | (293.56%) | 19.88% |
Accounts Payable Turnover |
— | — | — | — | — | 0.00 | 0.00 | — | 0.00 | 0.00 |
Average Days of Payables |
— | — | — | 0.00 | — | 0.00 | 0.00 | — | 0.00 | 0.00 |
Revenue per Share |
— | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
— | (0.05) | 0.00 | (0.27) | (0.18) | (0.74) | (4.37) | (0.59) | (0.09) | (0.05) |
Capex per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Payables |
— | — | — | — | — | 0.17 | 4.83 | — | 4.67 | 0.28 |
Average Assets |
— | 22.90 | 22.90 | 22.90 | 27.90 | 9.86 | 6.38 | 3.74 | 3.80 | 3.16 |
Average Common Equity |
— | 21.59 | — | 21.59 | 3.03 | 2.41 | (7.00) | (3.73) | 2.21 | (5.11) |
Capex to Sales |
— | — | 0.00 | — | — | — | — | — | — | — |
Net Profit Margin |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates